Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer
AssigneeKing Abdullah University of Science and Technology
InventorsVladimir Bajic, Roberto Incitti, Hicham Mansour
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns particular biomarkers for screening, diagnosing and/or prognosticating colorectal cancer, in particular in an accurate manner. The methods and compositions concern analysis of methylation patterns of one or more of 176 methylatable genomic DNA regions identified as described herein. In particular embodiments there are methods of detecting methylatable regions in genomic sequences.
Claims10
A method of treating colorectal cancer (CRC) in a human subject, comprising:
- (a) assaying genomic nucleic acids from a sample comprising genomic DNA obtained from the human subject for the number of methylated nucleotides in the methylatable regions (MRs) of genomic DNA comprising SEQ ID NOs:
- 1-176,
- wherein the sample is selected from the group comprising tissue, blood, spittle, serum, plasma, urine, sputum, biopsy, and stool;
- (b) determining the methylation score (mSCORE) as defined by equation (1):
- mSCORE=COV (coverage)×mTOT (total methylation), (1)
- wherein the human subject is diagnosed as having colorectal cancer if the mSCORE within these 176 MRs as defined by equation (1) is greater than 577, and
- (c) treating the diagnosed human for CRC with an anticancer treatment.
A method of of treating colorectal cancer (CRC) in a human subject comprising,
- (a) assaying genomic nucleic acids from a colon biopsy sample obtained from the human subject for the number of methylated nucleotides in the methylatable regions (MRs) of genomic DNA comprising SEQ ID NOs:
- 1-176, wherein the human subject is diagnosed as having colorectal cancer if the methylation score within these 176 MRs as defined by equation (1) (mSCORE=COV (coverage)×mTOT (total methylation;
- is greater than 577, and
- (b) treating the human for CRC with an anticancer treatment.
A method of treating-colorectal cancer (CRC) in a human subject, comprising administering to a therapeutic agent for treating CRC to the subject wherein the subject has been diagnosed has having colorectal cancer by a method comprising the steps of (a) assaying genomic nucleic acids from a sample comprising genomic DNA obtained from the human subject for the number of methylated nucleotides in the methylatable regions (MRs) of genomic DNA comprising SEQ ID NOs:
- 1-176;
- and
- (b) determining the methylation score (mSCORE) as defined by equation (1):
- mSCORE=COV (coverage)×mTOT (total methylation), (1)
- wherein:
- the human subject is diagnosed as having colorectal cancer if the mSCORE within these 176 MRs as defined by equation (1) is greater than 577, wherein the sample is selected from the group comprising tissue, blood, spittle, serum, plasma, urine, sputum, biopsy, and stool.
Dependencies are inferred from the claim text.